Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: Superiority of free 25-OH D levels in detecting relationships

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages 4400-4409

  Kane, Lynn ^a   Moore, Kelly ^a   Lütjohann, Dieter ^b   Bikle, Daniel ^c,d   Schwartz, Janice B ^a,c  

^a Jewish Home of San Francisco   (United States)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ATORVASTATIN; CAMPESTEROL; CHOLESTEROL; COLECALCIFEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; COMMUNITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART RATE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TANDEM MASS SPECTROMETRY; VITAMIN DEFICIENCY; VITAMIN INTAKE;

ADMINISTRATION, ORAL; AGED; CHOLECALCIFEROL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LINEAR MODELS; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; VITAMIN D; VITAMINS;

EID: 84887479009     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1922     Document Type: Article

References (40)

1. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167: 1159-1165.
2. Michos ED, Blumenthal RS. Vitamin D supplementation and cardiovascular disease risk. Circulation. 2007;115: 827-828.
3. Autier P, Gandini S. VitaminDsupplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167: 1730-1737.
4. McGreevy C, Williams D. New insights about vitamin D and cardiovascular disease: a narrative review. Ann Intern Med. 2011;155: 820-826.
5. Schwartz J. Effects of vitamin D supplementation in atorvastatintreated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther. 2009;85(2): 198-203.
6. Ponda MP, Huang X, Odeh MA, Breslow JL, Kaufman HW. Vitamin D may not improve lipid levels: a serial clinical laboratory data study. Circulation. 2012;126: 270-277.
7. Carlson LA, Derblom H, Lanner A. Effect of different doses of vitamin D on serum cholesterol and triglyceride levels in health men. Atherosclerosis. 1970;12(2): 313-317.
8. Gannagé-Yared M, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R. Effects of a short-term calcium and vitaminDtreatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest. 2003; 26(8): 748-753.
9. Adams CM, Reitz J, De Brabander JK, et al. Cholesterol and 25- hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involvingSCAPand Insigs. J BiolChem. 2004;279(50): 52772-52780.
10. Carbone LD, Rosenberg EW, Tolley EA, et al. 25-Hydroxyvitamin D, cholesterol, and ultraviolet irradiation. Metab Clin Exp. 2008; 57: 741-748.
11. Heikkinen A-M, Tuppurainen M, Niskanen L, Komulainen M, Penttila I, Saarikoski S. Long-term vitaminD3supplementationmay have adverse effects on serum lipids during postmenopausal hormone replacement thereapy. Eur J Endocrinol. 1997;137: 495-502.
12. Mak R. 1,25-dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int;. 1998;53: 1353-1357.
13. Maung K, Miyazaki A, Nomiyama H, Chang CC, Chang TY, Horiuchi S. Induction of acyl-coenzyme A:cholesterol acyltransferase-1 by 1,25-dihydroxyvitamin D(3) or 9-cis-retinoic acid in undifferentiated THP-1 cells. J Lipid Res. 2001;42(2): 181-187.
14. Major GC, Alarie F, Doré J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85(1): 54-59.
15. Ponda MP,DowdK, Finkielstein D, Holt PR, Breslow JL. The shortterm effects of vitamin D repletion on cholesterol: a randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2012; 32(10): 2510-2515.
16. Kampman E, Slattery ML, Caan B, Potter JD. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). Cancer Causes Control. 2000;11: 459-466.
17. Swinkels L, Maas A, Martens M, Parsons G, Rosmalen F. An immunoassay for free 25-hydroxy vitamin D. In: 43rd Oak Ridge Conference Emerging Technologies for 21st Century Diagnostics: April 14-15 2011. American Association for Clinical Chemistry. Baltimore, MD; 2011.
18. Byrdwell W, DeVries J, Exler J, et al. Analyzing vitamin D in foods and supplements: methodologic challenges. Am J Clin Nutr. 2008; 88(suppl):554S-557S.
19. Chen TC, Turner AK, Holick MF. A method for the determination of the circulating concentration of vitamin D. J Nutr Biochem. 1990; 1: 272-276.
20. Block G, Hartman AM, Naughton D. A reduced dietary questionnaire: development and validation. Epidemiology. 1990;1(1): 58-64.
21. Kulkarni K. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 2006;26: 787-802.
22. Lütjohann D, Brzezinka A, Barth E, et al. Profile of cholesterolrelated sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res. 2002;43(7): 1078-1085.
23. Teunissen CE, Mulder M, de Vente J, et al. Concentrations of different sterols in the striatum and serum of 3-nitropropionic acidtreated Wistar and Lewis rats. Neurochem Res. 2001;26(11):1237- 1244.
24. HolickM.VitaminDdeficiency.NEngl JMed. 2007;357: 266-281.
25. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94(1): 26-34.
26. Bikle D. Vitamin D: newly discovered actions require reconsideration of physiologic requirements. Trends Endocrinol Metab. 2010; 21(6): 375-384.
27. Wang H, Xia N, Yang Y, Peng D-Q. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2012;11: 42-50.
28. Jorde R, Grimnes G. Vitamin D and lipids: do we really need more studies? Circulation. 2012;126: 252-254.
29. Gupta A, Sexton R, Rudney H. Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. J Lipid Res. 1989;30: 379-386.
30. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H, Finnish Treat-to-Target Study Investigators. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med. 2003;141: 131-137.
31. van Himbergen TM, Matthan NR, Resteghini NA, et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res. 2009;50: 730-739.
32. Miettinen TA, Tilvis RS, Kesäniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population.AmJ Epidemiol. 1990;131: 20-31.
33. Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system byUVradiation: more than just the effects of vitamin D? Nat Rev Immunol. 2011;11: 584-596.
34. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab. 1986;63: 954-959.
35. Fu L, Yun F, Oczak M, Wong BY, Vieth R, Cole DE. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem. 2009;42: 1174-1177.
36. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95(2): 471-478.
37. Christakos S, Hewison M, Gardner DG, et al. Vitamin D: beyond bone. Ann NY Academy Sci. 2013;1287: 45-58.
38. Lisse TS, Hewison M, Adams JS. Hormone response element binding proteins: novel regulators of vitamin D and estrogen signaling. Steroids. 2011;76(4): 331-339.
39. Bhan I, Powe CE, Berg AH, et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitaminDin incident hemodialysis patients. Kidney Intl. 2012;82: 84-89.
40. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93: 677-681.